gutflix
GI learning, personalised

Summary

OUTCOMES OF PHOSPHORUS-32 (32P) MICROPARTICLE INTRA-TUMORAL IMPLANTATION ADDED TO CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA

William Hsieh

UEG Week Copenhagen 2023 Poster

Pancreas

October 15, 2023

A retrospective multicentre study of 14 metastatic pancreatic adenocarcinoma patients treated with EUS-guided phosphorus-32 microparticle implantation plus chemotherapy achieved 100% local disease control at 3 months.

KEY POINTS

- All 14 patients achieved local disease control at 3 months post-implantation (10 stable disease, 4 partial response), with median 25% reduction in primary tumour size and CA19-9 decline from 856.5 to 72 U/mL.
- Median progression-free survival was 5.6 months and overall survival was 13.9 months after phosphorus-32 implantation, with most progression occurring at distant sites (8 patients) rather than locally.
- The procedure showed 100% technical success with no Grade 4 or 5 toxicities; only 3 patients (21.4%) experienced Grade 1 or 2 adverse events also attributable to chemotherapy.
- One patient (7%) achieved sufficient response to undergo R0 resection after treatment with the combination approach.
- The authors conclude the approach is feasible and safe and recommend prospective trial evaluation; two authors are affiliated with OncoSil Medical.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/a883b4c4-743c-11ee-8e6c-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.